Pacific Biosciences (PACB) Stock Statistics & Valuation Metrics

Pacific Biosciences has a market cap or net worth of $381.47M. The enterprise value is $756.39M.

Pacific Biosciences has 300,370,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pacific Biosciences’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -39.10%.

The current PE Ratio of Pacific Biosciences is ―. Pacific Biosciences’s PEG ratio is ―.

In the last 12 months, Pacific Biosciences had revenue of 154.01M and earned -309.85M in profits. Earnings per share was -1.13.

In the last 12 months, operating cash flow was -149.55M and capital expenditures -2.77M, giving a free cash flow of -152.31M billion.

Pacific Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Pacific Biosciences upcoming earnings date is Nov 10, 2025, TBA (Confirmed).

Pacific Biosciences as a current ratio of 7.48, with Debt / Equity ratio of 1137.15%

In the past 12 months, Pacific Biosciences has paid 316.00K in taxes.

Pacific Biosciences EV to EBITDA ratio is -4.61, with an EV/FCF ratio of -5.27.

Pacific Biosciences has $314.74M in cash and marketable securities with $699.22M in debt, giving a net cash position of -$384.49M billion.

Gross margin is -210.54%, with operating margin of -307.97%, and net profit margin of -201.18%.

The average price target for Pacific Biosciences is $1.99, which is 11.43% higher than the current price. The consensus rating is Moderate Buy